IL6R polymorphisms can serve as a potential biomarker in predicting response to sarilumab in RA patients
Comparable risk of major adverse cardiovascular events in patients with autoimmune diseases receiving upadacitinib, methotrexate and adalimumab
Study highlights the need to improve cardiovascular preventive services in patients with rheumatoid arthritis
